Invivyd Sees Covid-19 Prevention Treatment Revenue of Up to $200 Million This Year
By Sabela Ojea
Invivyd said it expects net product revenue of $150 million to $200 million this year from its Covid-19 preventive treatment, shortly after receiving an emergency use authorization from the Food and Drug Administration.
The biotechnology company on Thursday said that based on expected net product revenue on the treatment for the year, it also expects to end 2024 with at least $55 million in cash and cash equivalents.
The pre-Covid-19 exposure injection Pemgarda is now commercially available for purchase across the U.S.
On March 22, Invivyd said the FDA granted the emergency use authorization to its Pemgarda monoclonal antibody to prevent Covid-19 in immunocompromised adolescents and adults.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 04, 2024 16:38 ET (20:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks